Jounce Therapeutics, Inc. JNCE
We take great care to ensure that the data presented and summarized in this overview for Jounce Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JNCE
View allLatest Institutional Activity in JNCE
Top Purchases
Top Sells
About JNCE
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at JNCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2023
|
Tang Kevin C Director |
BUY
Other acquisition or disposition
|
Indirect |
10,000
+50.0%
|
$97,370,000
$9737.7 P/Share
|
|
May 03
2023
|
Tang Kevin C Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,300,087
-100.0%
|
$5,300,087
$1.85 P/Share
|
|
May 03
2023
|
Concentra Biosciences, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
10,000
+50.0%
|
$97,370,000
$9737.7 P/Share
|
|
May 03
2023
|
Perry A Karsen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,000
-100.0%
|
-
|
|
May 03
2023
|
Richard /Ca/ Murray Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
188,778
-100.0%
|
-
|
|
May 03
2023
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
66,018
-69.5%
|
-
|
|
May 03
2023
|
Robert Kamen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
33,875
-100.0%
|
-
|
|
May 03
2023
|
Robert Kamen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
60,975
-100.0%
|
-
|
|
Apr 04
2023
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
39,228
-17.2%
|
$39,228
$1.85 P/Share
|
|
Mar 14
2023
|
Tang Kevin C Director |
BUY
Open market or private purchase
|
Indirect |
20,286
+0.38%
|
$20,286
$1.02 P/Share
|
|
Mar 13
2023
|
Tang Kevin C Director |
BUY
Open market or private purchase
|
Indirect |
65,701
+1.23%
|
$0
$0.99 P/Share
|
|
Jan 10
2023
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
7,781
-10.54%
|
$7,781
$1.12 P/Share
|
|
Jan 10
2023
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
24,879
-9.84%
|
$24,879
$1.12 P/Share
|
|
Jan 10
2023
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,126
-4.72%
|
$5,126
$1.12 P/Share
|
|
Jan 10
2023
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,182
-7.7%
|
$9,182
$1.12 P/Share
|
|
Jan 09
2023
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
6,315
-7.88%
|
$6,315
$1.1 P/Share
|
|
Jan 09
2023
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
20,191
-7.39%
|
$20,191
$1.1 P/Share
|
|
Jan 09
2023
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,159
-3.69%
|
$4,159
$1.1 P/Share
|
|
Jan 09
2023
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,452
-5.88%
|
$7,452
$1.1 P/Share
|
|
Aug 01
2022
|
Hugh M Cole Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.63%
|
-
|